Join Mike Clague's Patreon Community

MIKE CLAGUE - Peer-Reviewed Publications

​

Mike D. Clague, BSc (Anatomy), Adjunct Lecturer (Practice), Monash University

​

ORCID iD: 0009-0007-3540-3247

​

References in APA 7th edition format, ordered chronologically. Reconciled against Mike Clague’s ORCID record and verified against publisher and PubMed metadata, July 2026.

​

Goodman, G. J., & Clague, M. D. (2016). A rethink on hyaluronidase injection, intraarterial injection, and blindness: Is there another option for treatment of retinal artery embolism caused by intraarterial injection of hyaluronic acid? Dermatologic Surgery, 42(4), 547–549. https://doi.org/10.1097/DSS.0000000000000670

​

Shamban, A., Clague, M. D., von Grote, E., & Nogueira, A. (2018). A novel and more aesthetic injection pattern for malar cheek volume restoration. Aesthetic Plastic Surgery, 42(1), 197–200. https://doi.org/10.1007/s00266-017-0981-1

​

Goodman, G. J., Magnusson, M. R., Callan, P., Roberts, S., Hart, S., McDonald, C. B., Clague, M., Rudd, A., Bekhor, P. S., Liew, S., Molton, M., Wallace, K., Corduff, N., Arendse, S., Manoharan, S., Shamban, A., Heydenrych, I., Bhatia, A. C., Peng, P., . . . Kosenko, D. E. (2020). A consensus on minimizing the risk of hyaluronic acid embolic visual loss and suggestions for immediate bedside management. Aesthetic Surgery Journal, 40(9), 1009–1021. https://doi.org/10.1093/asj/sjz312

​

Goodman, G. J., Magnusson, M. R., Callan, P., Roberts, S., Hart, S., McDonald, C. B., Liew, S., Porter, C., Corduff, N., & Clague, M. (2021). Neither positive nor negative aspiration before filler injection should be relied upon as a safety maneuver. Aesthetic Surgery Journal, 41(4), NP134–NP136. https://doi.org/10.1093/asj/sjaa215

​

Goodman, G. J., Magnusson, M. R., Callan, P., Roberts, S., Hart, S., Lin, F., Rahman, E., McDonald, C. B., Liew, S., Porter, C., Corduff, N., & Clague, M. (2022). Aspiration before tissue filler—An exercise in futility and unsafe practice. Aesthetic Surgery Journal, 42(1), 89–101. https://doi.org/10.1093/asj/sjab036

​

Lin, F., Goodman, G. J., Magnusson, M., Callan, P., Roberts, S., Hart, S., Rahman, E., McDonald, C. B., Liew, S., Porter, C., Corduff, N., & Clague, M. (2022). Movement of the syringe during filler aspiration: An ultrasound study. Aesthetic Surgery Journal, 42(10), 1109–1116. https://doi.org/10.1093/asj/sjac032

​

Goodman, G. J., McDonald, C. B., Lim, A., Porter, C. E., Deva, A. K., Magnusson, M., Patel, A., Hart, S., Callan, P., Rudd, A., Roberts, S., Wallace, K., Bekhor, P., Clague, M., Williams, L., Corduff, N., Wines, N., Al-Niaimi, F., Fabi, S. G., . . . Poon, T. (2023). Making sense of late tissue nodules associated with hyaluronic acid injections. Aesthetic Surgery Journal, 43(6), NP438–NP448. https://doi.org/10.1093/asj/sjad028

​

Clague, M. D., Goodman, G., Taing, C., Stuart, L., Orsatti, M. L., Holbrook, J., Delaney, J., & Mackay, B. (2024). Hyperdiluted botulinum toxin and intense pulsed light treatment: A case series to illustrate a novel protocol for hypertrophic scar reduction. Plastic and Aesthetic Nursing, 44(2), 116–123. https://doi.org/10.1097/PSN.0000000000000551

​

Currie, E., Granata, B., Goodman, G., Rudd, A., Wallace, K., Rivkin, A., Hart, S., Porter, C. E., Harris, S., Walker, L., Lin, F., Corduff, N., Davies, N., Roberts, S., Clague, M., Callan, P. P., McDonald, C., Magnusson, M., Tsirbas, A., . . . Welsh, B. (2024). The use of hyaluronidase in aesthetic practice: A comparative study of practitioner usage in elective and emergency situations. Aesthetic Surgery Journal, 44(6), 647–657. https://doi.org/10.1093/asj/sjae009

​

Goodman, G. J., Lim, A., Hart, S., Callan, P., Boxley, S. G., McDonald, C. B., Lin, F., Clague, M., Corduff, N., Roberts, S., Rudd, A., Wallace, K., Kumar, N., Ciconte, A., Al-Niaimi, F., Arendse, S., Bekhor, P., Yap, L.-M., Ahern, M. A., . . . Williams, L. (2025). Botulinum toxin: Surely, we can do better? Optimizing results beyond on-label techniques and teaching. Aesthetic Surgery Journal Open Forum, 7, ojaf032. https://doi.org/10.1093/asjof/ojaf032

 

Goodman, G. J., Harris, S., Currie, E., Granata, B., Wallace, K., Corduff, N., Bekhor, P., Clague, M., Hart, S., Lin, F., Davies, N., McDonald, C., Porter, C. E., Magnusson, M., Roberts, S., Walker, L., Callan, P. P., Rudd, A., Tsirbas, A., . . . Welsh, B. (2025). Response to: Hyaluronidase availability beyond the aesthetic office: A shared responsibility for safety in filler complications. Aesthetic Surgery Journal, 45(7), NP139–NP141. https://doi.org/10.1093/asj/sjaf061

 

Sansome, S., Clague, M., Convery, C., Davies, E., Fairris, C., Goodman, G., Harris, S., Hawkes, E., Hay, G., Murray, G., et al. (2026). Consensus guidelines for the management of tissue filler–induced vision loss in the United Kingdom. Aesthetic Surgery Journal, 46(5), 563–568. https://doi.org/10.1093/asj/sjag002

​

MANDATORIES 

​

Please ensure you have read and understood our pre-treatment protocols to ensure the best possible outcome for your cosmetic journey. Avoid alcohol consumption for 24 hours prior to your appointment.

​

SCULPTRA® is a poly-L-lactic acid implant liquid that is injected by a healthcare professional into or below the skin to increase volume of depressed areas, particularly to correct skin depressions. Class III Medical Device. Sculptra® may also be used for large volume restoration and/or correction of the signs of facial fat loss. Sculptra® has risks and benefits. Sculptra® treatment may result in injection site reactions and pain. Ask your healthcare professional to explain the range of possible side effects and tell them if any side effects concern you. Sculptra® should not be injected into skin that is inflamed or infected. Exposure to excessive sunlight or UV lamp exposure should be avoided until redness or swelling has resolved. Sculptra® is not recommended for people taking blood thinning medicines and has not been tested in pregnant or breast-feeding women or those aged under 18 years. Lasts for 12-25 months. ALWAYS FOLLOW THE INSTRUCTIONS YOU ARE GIVEN.  Galderma Australia, Sydney. Distributed by Healthcare Logistics Auckland.

​

RESTYLANE®

ASK YOUR HEALTH CARE PROFESSIONAL IF RESTYLANE® IS RIGHT FOR YOU.

RESTYLANE® is an unfunded medicine device. Product and treatment costs apply. Restylane®, Class III medical device, is a gel containing hyaluronic acid 20 mg/mL and lidocaine 0.3%, for injection by a healthcare professional into or below the skin to smooth facial wrinkles and enhance lips. Restylane® has risks and benefits. Ask your healthcare professional if Restylane® is right for you and to explain the possible side effects. Tell them if any side effects concern you. ALWAYS FOLLOW THE INSTRUCTIONS YOU ARE GIVEN. For precautions and contraindications, see www.galdermaaesthetics.com/nz. Restylane® is a registered trademarks of Galderma Holding S.A.

​

ART FILLER®

Containing low & high molecular weight hyaluronic acid, is a Class III medical device for the treatment of facial contours for redefinition, laxity and remodelling where skin laxity is a problem. ART FILLER® has risks and benefits. Do not use with treatments such a laser resurfacing or medium deep skin-peeling. Caution in people on blood thinning medicines. Do not inject into inflamed areas or intravenously or intramuscularly. Possible side effects: pain and swelling at injection site. Distributed by Cryomed Aesthetics Ltd. Auckland. 

​

BOTOX®

ASK YOUR HEALTH CARE PROFESSIONAL IF BOTOX® IS RIGHT FOR YOU.

BOTOX® is an unfunded medicine for aesthetic procedures so you will need to pay for the medicine and any other charges. BOTOX® is a Prescription Medicine containing 50,100 or 200 units of clostridium botulinum Type A toxin complex for injection. It is used for the treatment of frown lines, crows feet and horizontal forehead lines. It should be administered only by trained medical professionals. Cautions: people with defective neuro-muscular transmission disorders, presence of infection at site of injection, glaucoma, pregnancy and lactation. Possible side effects include headaches, pain, burning or redness at injection site, local muscle weakness including drooping eye lids, lack of feeling & nausea. Talk to your specialist about the benefits/risks of this procedure or if you have concerns or side effects. For more information, please refer to the BOTOX® Consumer Medicine Information on the MEDSAFE website http://www.medsafe.govt.nz Note: BOTOX® treatment lasts about four months and after this time further courses of treatment may be necessary. Speak to your specialist about your own situation. BOTOX® and its design are trademarks of Allergan, Inc., an AbbVie company.